OrthoPediatrics Corp. (NASDAQ:KIDS) Short Interest Up 13.2% in September

OrthoPediatrics Corp. (NASDAQ:KIDS) saw a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 961,700 shares, an increase of 13.2% from the September 15th total of 849,900 shares. Currently, 5.9% of the company’s stock are short sold. Based on an average daily trading volume, of 179,000 shares, the short-interest ratio is currently 5.4 days.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on KIDS shares. Needham & Company LLC reiterated a “buy” rating and issued a $42.00 target price on shares of OrthoPediatrics in a research note on Friday, September 13th. JMP Securities reissued a “market outperform” rating and issued a $50.00 price target on shares of OrthoPediatrics in a report on Friday, September 13th. Finally, Truist Financial lowered their price target on shares of OrthoPediatrics from $34.00 to $28.00 and set a “hold” rating on the stock in a report on Monday.

OrthoPediatrics Stock Up 2.7 %

OrthoPediatrics stock opened at $27.75 on Thursday. The stock has a market cap of $661.25 million, a P/E ratio of -28.91 and a beta of 1.17. The company has a quick ratio of 1.96, a current ratio of 4.90 and a debt-to-equity ratio of 0.03. OrthoPediatrics has a twelve month low of $23.10 and a twelve month high of $36.23. The company’s 50-day moving average price is $28.45 and its two-hundred day moving average price is $30.09.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Monday, August 5th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.08. OrthoPediatrics had a negative net margin of 14.35% and a negative return on equity of 5.44%. The company had revenue of $52.80 million for the quarter, compared to analysts’ expectations of $52.40 million. As a group, analysts expect that OrthoPediatrics will post -0.92 EPS for the current year.

Insider Transactions at OrthoPediatrics

In other news, General Counsel Daniel J. Gerritzen sold 10,000 shares of the stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $29.30, for a total transaction of $293,000.00. Following the completion of the transaction, the general counsel now directly owns 77,304 shares in the company, valued at $2,265,007.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 31.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Wasatch Advisors LP boosted its position in shares of OrthoPediatrics by 21.2% during the 1st quarter. Wasatch Advisors LP now owns 501,310 shares of the company’s stock worth $14,618,000 after acquiring an additional 87,657 shares in the last quarter. Harbor Capital Advisors Inc. boosted its position in OrthoPediatrics by 649.0% in the second quarter. Harbor Capital Advisors Inc. now owns 67,057 shares of the company’s stock valued at $1,929,000 after buying an additional 58,104 shares in the last quarter. Kennedy Capital Management LLC acquired a new stake in OrthoPediatrics in the first quarter valued at approximately $2,894,000. Divisadero Street Capital Management LP acquired a new stake in OrthoPediatrics in the second quarter valued at approximately $514,000. Finally, Wellington Management Group LLP acquired a new stake in OrthoPediatrics in the fourth quarter valued at approximately $10,214,000. 69.05% of the stock is owned by institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.